ストックスクリーナーアプリを入手
0.7556
3.00%
0.022
プレマーケット:
.66
-0.0956
-12.65%
Citius Pharmaceuticals Inc (CTXR) 最新ニュース
Citius Pharmaceuticals (NASDAQ:CTXR): What Does Today’s Program Priorities Checkpoint Mean? - Kalkine Media
Is Citius Pharmaceuticals (CTXR) Worth the Investment After Q3 E - GuruFocus
Citius Pharmaceuticals Reports LYMPHIR Revenue Growth, Explores CAR-T Combination - The Clinical Trial Vanguard
Citius Pharma Reports First LYMPHIR Revenue of $7.1M in Nine Months - Minichart
Citius Pharmaceuticals Reports Q3 2026 Financial Results and LYMPHIR Progress - Intellectia AI
CTXR: LYMPHIR's launch drove $7.1M revenue and 77% gross margin, offset by higher launch costs - TradingView
Citius Oncology (CTOR) grows LYMPHIR sales but posts $41M nine-month loss - Stock Titan
Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update - PR Newswire
Citius Pharmaceuticals (CTXR) holders report 3.0M-share, 9.9% beneficial stake - Stock Titan
CTXR Q3'26 Earnings: EPS estimate is (0.36) USD - TradingView
Citius Oncology appoints independent director Peri to board of directors - ROI-NJ
People on the Move: Jonathan Peri, Ph.D., J.D., Joins Citius Oncology’s Board of Directors - BioBuzz
Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri - Morningstar
Citius Pharmaceuticals expands Citius Oncology board to nine with appointment of Jonathan Peri - Traders Union
Citius Oncology Adds Jonathan Peri to Board as LYMPHIR Commercialization Advances - citybiz
Citius Oncology appoints Jonathan Peri to board of directors - Investing.com
Citius Pharmaceuticals Inc (CTXR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BREAKING: THE PRINTING HAS STARTED! Robert De Niro (xWXxQcdGpe) - Mshale
Citius Oncology reports strong LYMPHIR U.S. launch momentum - TipRanks
Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment - Morningstar
Citius Oncology's LYMPHIR is in 42 institutions with near-universal coverage - Stock Titan
Citius Pharmaceuticals (CTXR) Advances 5.7% to $0.63; Key Resistance at $0.66 in FocusVolatility Surface - dars.gov.et
Citius Pharmaceuticals (CTXR) Tumbles 9.81% to $0.57 as Biotech Stock Approaches Critical SupportValue Stock Ideas - dars.gov.et
Citius Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:CTXR - TradingView
Citius Pharmaceuticals Inc (CTXR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CTXR|Citius Pharmaceuticals Inc|Price:0.490|Chg%:-0.027 - TradingKey
Citius Pharmaceuticals Inc (CTXR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Citius Pharmaceuticals Inc (CTXR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Citius Pharmaceuticals Inc (CTXR) Institutional Confidence - TradingKey
Citius Pharmaceuticals Inc (CTXR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TradingKey - TradingKey
CTXR|Citius Pharmaceuticals Inc|Price:0.682|Chg%:+0.040 - TradingKey
Citius Oncology Inc (CTOR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Citius Pharmaceuticals (CTXR) Slips 2%, Hovers Above Key Support at $0.49Put Flow Alert - dars.gov.et
Citius Oncology Inc (CTOR) Institutional Confidence - TradingKey
Citius Pharmaceuticals (CTXR) Sidoti Micro-Cap Virtual Conference Summary - Quartr
Citius Oncology expands sales team for LYMPHIR launch By Investing.com - Investing.com Nigeria
Citius Oncology expands sales team for LYMPHIR launch - Investing.com
Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption - Morningstar
Citius Oncology expands LYMPHIR launch team nationwide - scanx.trade
Citius Oncology (Nasdaq: CTOR) sets $18M stock deal at $1.09 to back LYMPHIR launch - Stock Titan
Citius Oncology (CTOR) Registration filing Summary - Quartr
Enterprise value to revenue forward of Citius Pharmaceuticals, Inc. – NASDAQ:CTXR - TradingView
Citius Pharmaceuticals (CTXR) Edges Lower, Testing Key Support at $0.51Long Short Pair - dars.gov.et
Enterprise value to revenue forward of Citius Pharmaceuticals Inc – LS:A40MD0 - TradingView
CTXR News | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR) - ChartMill
Citius Pharmaceuticals updates pipeline as investors track CTXR stock - Ad-hoc-news.de
Citius Pharmaceuticals Inc (NASDAQ:CTXR) Is A Biotech Runner: Here's Why - Insider Financial
Citius Pharmaceuticals Q4 2025 Earnings: EPS Miss Exceeds 45% as Pre-Revenue Biotech Navigates Clinical MilestonesAdjusted Earnings Analysis - DonanımHaber
A40MD0 Forecast — Price Target — Prediction for 2027 - TradingView
Price to earnings forward of Citius Pharmaceuticals, Inc. – NASDAQ:CTXR - TradingView
Price to earnings forward of Citius Pharmaceuticals, Inc. – BOATS:CTXR - TradingView
Enterprise value to EBIT forward of Citius Pharmaceuticals, Inc. – NASDAQ:CTXR - TradingView
47N0 Forecast — Price Target — Prediction for 2027 - TradingView
Price to sales forward of Citius Pharmaceuticals, Inc. – BOATS:CTXR - TradingView
Enterprise value to EBITDA forward of Citius Pharmaceuticals, Inc. – NASDAQ:CTXR - TradingView
Citius Pharmaceuticals Inc Actuals & Estimates (FWB:47N0) - TradingView
Enterprise value to revenue forward of Citius Pharmaceuticals, Inc. – BOATS:CTXR - TradingView
Enterprise value to EBITDA forward of Citius Pharmaceuticals, Inc. – BOATS:CTXR - TradingView
Enterprise value to EBIT forward of Citius Pharmaceuticals, Inc. – BOATS:CTXR - TradingView
Citius Pharmaceuticals Inc Actuals & Estimates (NASDAQ:CTXR) - TradingView
CTXR Forecast — Price Target — Prediction for 2027 - TradingView
Citius Pharmaceuticals updates I/ ONTAK launch progress, shares trade on Nasdaq - AD HOC NEWS
Citius Pharmaceuticals Inc (CTXR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Citius Pharmaceuticals (CTXR) price target increased by 20.00% to 6.12 - MSN
0.52%
0.07%
大文字化:
|
ボリューム (24 時間):